Latest
simplywall.st Market update
News archive search
Search the Newsreel
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
- Showing
- 1–36
- Matches
- 187
- Sources here
- 23
- Companies here
- 16
Search results
Stored financial headlines
Active search
187 matching headlines
Ticker or company: KGMain company stories
Search results
Matching headlines
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
How Ginkgo Bioworks Holdings Inc. Class A (DNA) Affects Rotational Strategy Timing
The article analyzes Ginkgo Bioworks Holdings Inc. Class A (DNA) stock performance and its impact on rotational strategy timing. It highlights a weak sentiment signaling long-term weakness resumption and identifies a significant short setup with a 100.0:1 risk-reward ratio. The report provides three AI-generated …
DNA
main company
Sharemaestro market context
Price below Trend Line
52 weeks -45.9% · Next-week setup negative 42.3%
CEWE Stiftung & Co. KGaA Q2 Earnings Call Highlights
Key Points Interested in CEWE Stiftung & Co. KGaA? Here are five stocks we like better. Core photo-finishing remained the main growth engine: Second-quarter segment revenue rose 7.5%, supported by higher volumes and premiumization, while photo-book revenue increased 3%. CEWE reaffirmed its 2026 revenue …
CWC
main company
Sharemaestro market context
Price above Trend Line
52 weeks +8.2%
Stroeer SE & Co KGaA (SOTDY) (H1 2026) Earnings Call Highlights: Out-of-Home Strength ...
This article first appeared on GuruFocus. Revenue (H1): EUR1,037 million, up from EUR980 million in the prior year period; organic growth accelerated to 2.7%. Adjusted EBITDA (H1): EUR273 million, a 3% year-on-year increase from EUR266 million. Adjusted EBIT (H1): EUR150 million, up 6% from …
Sharemaestro market context Trend signal active 52 weeks -4.3%Remepy Raises $36 Million Series A to Expand Its Hybrid Drug™ Pipeline Through Pharmaceutical Partnerships and Advance Phase III of Hybridopa™ for Parkinson's Disease
Funding brings total capital raised to $62 million as the Company expands pharmaceutical co-development partnerships and accelerates the Hybrid Drug category NEW YORK, Aug. 12, 2026 /PRNewswire/ -- Remepy, the pioneer of Hybrid Drugs, today announced the closing of a $36 million Series A …
MRK
main company
Sharemaestro market context
Trend signal active
52 weeks +24.0%
EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: SOEC-Neuausrichtung führt zu Anpassung der EBIT-Prognose 2025/26; Aktualisierung der Auftragseingangs- und Umsatz-Erwartung auf Basis bisheriger Geschäftsentwicklung - boerse.de
NCH2
main company
Sharemaestro market context
Price below Trend Line
52 weeks -14.6%
Are Investors Undervaluing Fresenius SE & Co. (FSNUY) Right Now?
The proven Zacks Rank system focuses on earnings estimates and estimate revisions to find winning stocks. Nevertheless, we know that our readers all have their own perspectives, so we are always looking at the latest trends in value, growth, and momentum to find strong …
FRE
main company
Sharemaestro market context
Price above Trend Line
52 weeks +1.5% · Next-week setup positive 59.6%